Aligos Therapeutics, Inc.
No trades
No trades
Peers for comparison
−6.36 USD
−24.19 M USD
2.19 M USD
5.57 M
Last report date
Report period
EPS
Revenue
Company info
Sector
Industry
CEO
Lawrence M. Blatt
Website
Headquarters
South San Francisco
Founded
2018
IPO date
Oct 16, 2020
ISIN
US01626L2043
CUSIP
01626L204
FIGI
BBG00QX7QH68
Identifiers
ISIN US01626L2043
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.
Trade Review - ALGS
When stock showed up in screener showed a bullish continuation pattern on daily timeframe and a potential failure test / pullback on the higher timeframe downtrend, a bit near mean but was added to watchlist.
Execution chart.
Trade Overview
• Structure: Bullish Continuation (D)
• Position: Nea
ALGS | Aligos Therapeutics, Inc. Healthcare US Stocks NASDAQ
📈 Technical Chart Patterns & Trend Analysis 📉
Identifying potential trading opportunities based on trend analysis:
bullish divergence can on double bottom can be seen on daily frame
buy stop order will be a suitable option for trading in this scenario .
$ALGS can rise in the next daysContextual immersion trading strategy idea.
Aligos Therapeutics, Inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.
The demand for shares of the company looks higher than the supply.
This and other conditions can c
See all ideas
Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral
An aggregate view of professional's ratings.
Neutral
Neutral
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
Today, ALGS trades at 2.10 USD.
For broader market analysis, dive into the technicals on the Aligos Therapeutics, Inc. stock price chart and read the latest ALGS news:
– Weekly Recap: Q3 2026 results and $25 million Amoytop licensing deal
– Aligos Therapeutics Q3 net loss narrows on lower R&D costs
– Aligos Therapeutics 3Q 2026: EPS ($2.09) — 10-Q Summary
For broader market analysis, dive into the technicals on the Aligos Therapeutics, Inc. stock price chart and read the latest ALGS news:
– Weekly Recap: Q3 2026 results and $25 million Amoytop licensing deal
– Aligos Therapeutics Q3 net loss narrows on lower R&D costs
– Aligos Therapeutics 3Q 2026: EPS ($2.09) — 10-Q Summary
Markets don't sleep, here's what's going on with ALGS at the moment:
– Weekly Recap: Q3 2026 results and $25 million Amoytop licensing deal
– Aligos Therapeutics Q3 net loss narrows on lower R&D costs
– Aligos Therapeutics 3Q 2026: EPS ($2.09) — 10-Q Summary
See more updates in real-time with our News Flow.
– Weekly Recap: Q3 2026 results and $25 million Amoytop licensing deal
– Aligos Therapeutics Q3 net loss narrows on lower R&D costs
– Aligos Therapeutics 3Q 2026: EPS ($2.09) — 10-Q Summary
See more updates in real-time with our News Flow.
Aligos Therapeutics, Inc. is scheduled to release its next earnings report on Mar 11, 2027.
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
ALGS stock is 13.38% volatile and has beta coefficient of 1.64.
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like ALGS are typically less volatile than smaller companies
Track every detail on Aligos Therapeutics, Inc. stock chart and check out the list of the most volatile stocks — is Aligos Therapeutics, Inc. there?
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like ALGS are typically less volatile than smaller companies
Track every detail on Aligos Therapeutics, Inc. stock chart and check out the list of the most volatile stocks — is Aligos Therapeutics, Inc. there?
To understand the ALGS stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — +7.58%
– 1 week — −52.03%
– 1 month — −61.27%
ALGS all-time low was 1.92 USD (Nov 12, 2026), and its highest price is 937.75 USD (Jan 20, 2021). Find more dynamics in the Stock Heatmap and on the Aligos Therapeutics, Inc. stock chart.
– 1 day — +7.58%
– 1 week — −52.03%
– 1 month — −61.27%
ALGS all-time low was 1.92 USD (Nov 12, 2026), and its highest price is 937.75 USD (Jan 20, 2021). Find more dynamics in the Stock Heatmap and on the Aligos Therapeutics, Inc. stock chart.
Aligos Therapeutics, Inc. market capitalization is 14.80 M, representing the total value of all its outstanding shares (price × shares outstanding).
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Aligos Therapeutics, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Aligos Therapeutics, Inc. stacks up against other companies
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Aligos Therapeutics, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Aligos Therapeutics, Inc. stacks up against other companies
The safest way to buy Aligos Therapeutics, Inc. stocks is through a reliable broker. Create an account, fund it, and place a buy order.
You can trade ALGS directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
You can trade ALGS directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
As of Nov 14, 2026, the company has 82 employees.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Investing in Aligos Therapeutics, Inc. depends on your goals, risk tolerance, and market conditions. It’s essential to analyze the stock before making a decision.
First, study Aligos Therapeutics, Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our ALGS technicals – signals based on essential indicators calculations:
– Today — sell
– 1-week — strong sell
– 1-month — sell
Combine fundamental and technical analysis for better results.
First, study Aligos Therapeutics, Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our ALGS technicals – signals based on essential indicators calculations:
– Today — sell
– 1-week — strong sell
– 1-month — sell
Combine fundamental and technical analysis for better results.
Aligos Therapeutics, Inc. stock ticker depends on the exchange where it’s listed. On the NASDAQ, its primary exchange, Aligos Therapeutics, Inc. stocks trade under the symbol ALGS.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
ALGS earnings for the last quarter are −2.09 USD per share, whereas the estimation was −2.28 USD, resulting in a 8.27% surprise. The estimated earnings for the next quarter are −2.03 USD per share.
How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one
Follow other essential metrics in Aligos Therapeutics, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one
Follow other essential metrics in Aligos Therapeutics, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
Aligos Therapeutics, Inc. revenue for the last quarter amounts to 2.87 M USD despite the estimated figure of 4.85 M USD. In the next quarter revenue is expected to reach 537.50 K USD.
How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance
Follow other essential metrics in Aligos Therapeutics, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses
How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance
Follow other essential metrics in Aligos Therapeutics, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses
Yes, you can track Aligos Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
ALGS net income for the last quarter is −21.86 M USD, while the quarter before that showed −1.50 M USD of net income which accounts for −1.35 K% change.
How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result
Follow other essential metrics in Aligos Therapeutics, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result
Follow other essential metrics in Aligos Therapeutics, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
No, Aligos Therapeutics, Inc. does not currently pay dividends to its shareholders.
Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.
What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.
What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
ALGS reached its all-time high of 937.75 USD on Jan 20, 2021. Its all-time low was 1.92 USD and was reached on Nov 12, 2026.
Explore the Aligos Therapeutics, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Explore the Aligos Therapeutics, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Aligos Therapeutics, Inc. EBITDA is −71.41 M USD, with an EBITDA margin of −3.98 K%.
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Aligos Therapeutics, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Aligos Therapeutics, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
Analyst forecasts suggest a price range between 20.00 USD and 51.00 USD for ALGS, based on current estimates.
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance





